5-lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 1, 1998, Pages 219-229

  Wright, Laurel ^a   Tuder, Rubin M ^a   Wang, Jun ^a   Cool, Carlyne D ^a   Lepley, Robert A ^a   Voelkel, Norbert F ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LUNG ALVEOLUS MACROPHAGE; LUNG INFILTRATE; MEDIATOR RELEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR RESISTANCE;

EID: 0031919455     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.1.9704003     Document Type: Article

References (31)

1. Wagenvoort, C. A., and N. Wagenvoort. 1970. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42:1163-1184.
2. . Pietra, G. G., W. D. Edwards, J. M. Kay, S. Rich, J. Kernis, B. Schloo, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, A. P. Fishman, R. M. Goldring, B. M. Groves, P. S. Levy, L. M. Reid, C. E. Vreim, and G. W. Williams. 1987. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Respiration 52: 81-85.
3. Tuder, R. M., B. Groves, D. Badesch, and N. F. Voelkel. 1994. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144: 275-285.
4. Caslin, A. W., D. Heath, B. Madden, M. Yacoub, J. R. Gosney, and P. Smith. 1990. The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology 16:9-19.
5. Cool, C. D., D. Kennedy, N. F. Voelkel, and R. M. Tuder. 1997. Pathogeneis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum. Pathol. 434-442.
6. Giaid, A., M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy, H. Shennib, S. Kimura, T. Masaki, W. P. Duguid, and D. J. Stewart. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N. Engl. J. Med. 328:1732-1739.
7. Botney, M. D., W. C. Parks, E. C. Crouch, K. Stenmark, and R. P. Mecham. 1992. Transforming growth factor-B1 is decreased in remodeling hypertensive bovine pulmonary arteries. J. Clin. Invest. 89:1629-1635.
8. Tuder, R. M., B. E. Flook, and N. F. Voelkel. 1995. Increased gene expression for VEGF and VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia: modulation of gene expression by nitric oxide. J. Clin. Invest. 95:1798-1807.
9. Meyrick, B., and L. Reid. 1979. Development of pulmonary arterial changes in rats led Crotalaria spectabilis. Am. J. Pathol. 94:37-50.
10. Herget, J., F. Palecek, P. Preclik, M. Cermakova, M. Vizek, and M. Petrovicka. 1981. Pulmonary hypertension induced by repeated pulmonary inflammation in the rat. J. Appl. Physiol. Respir. Environ. Exercise Physiol. 51:755-761.
11. Wilson, D. W., H. J. Segall, L. C. Pan, and S. K. Dunston. 1989. Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc. Res. 38:57-80.
12. Meyrick, B., and K. L. Brigham. 1986. Repeated Escherichia coli endotoxin-induced pulmonary inflammation causes chronic pulmonary hypertension in sheep: structural and functional changes. Lab. Invest. 55:164-176.
13. Ono, S., J. Y. Wescott, and N. F. Voelkel. 1992. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J. Appl. Pysiol. 73:1084-1092
14. Voelkel, N. F., R. M. Tuder, K. Wade, M. Hoper, R. A. Lepley, J. L. Goulet, B. H. Koller, and F. Fitzpatrick. 1996. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hyprtension in hypoxic rats. J. Clin. Invest. 97: 2491-2498.
15. Goetzl, E. J., S. An, and W. L. Smith. 1995. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 9:1051-1058.
16. Ford-Hutchinson, A. W., M. Gresser, and R. N. Young. 1994. 5-Lipoxygenase. Annu. Rev. Biochem. 63:383-417.
17. Samuelsson, B. 1983. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575.
18. MacDermot, J., C. R. Kelsey, K. A. Waddell, R. Richmond, R. K. Knight, P. T. Cole, C. T. Dollery, D. N. Landon, and A. I. Blair. 1984. Synthesis of leukotriene B4 and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrophotometry. Prostaglandins 27:163-177
19. Coffey, M. J., S. E. Wilcoxen, and M. Peters-Golden. 1994. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies dilterentiation of peripheral blood monocytes into alveolar macrophages Am. J. Respir. Cell Mol. Biol. 11:153-158.
20. Woods, J. W., M. J. Coffey, T. G. Brock, I. I. Singer, and M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 95:2035-2046.
21. Rouzer, C. A., and S. J. Kargman. 1988. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. Biol. Chem. 263:10980-10988.
22. Coffey, M., M. Peters-Golden, J. C. Fanlone, and P. H. S. Sporn. 1992. Membrane association of active 5-lipoxygenase in resting cells: evidence for novel regulation of the enzyme in the rat alveolar macrophage. J. Biol. Chem. 267:570-576.
23. Kargman, J., P. J. Vickers, and J. F. Evans. 1992. A23187-induced translocation of 5-lipoxygenase in osteosareoma cells. J. Cell Biol. 119:1701-1709.
24. Merz, H., R. Malisius, S. Mannweiler, R. Zhou, W. Hartmann, K. Orscheschek, P. Moubayed, and A. C. Feller. 1995. Methods in laboratory investigation. Immunomax: a maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab. Invest. 73:149-156.
25. Weidner, N. 1995. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147:9-19.
26. Wilborn, J., M. Baille, M. Coffey, M. Burdick, R. Strieter, and M. Peters-Golden. 1996. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97:1827-1836.
27. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-221.
28. Tang, D. G., Y. Q. Chen and K. V. Honn. 1996. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 93:5241-5246.
29. Avis, I. M., M. Jett, T. Boyle, M. D. Vos, T. Moody, A. M. Treston, A. Martinez, and J. L. Mulshine. 1996. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signalling. J. Clin. Invest. 97:806-813.
30. Anderson, K. M., J. Levin, and A. Jajeh. 1993. Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC-41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandin Leukot. Essen. Fatty Acids 48:323.
31. Lepley, R. A., and F. A. Fitzpatrick. 1994. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J. Biol. Chem. 269:24163-24168.